Delcath Systems, Inc. - 10-Q Summary (Period Ended June 30, 2009)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Delcath Systems, Inc., a development-stage medical technology company, for the period ended June 30, 2009. The company develops the Delcath Percutaneous Hepatic Perfusion (PHP) System, a device designed to administer high-dose chemotherapy directly to the liver. The company has no commercial revenues and is currently focused on completing a Phase III clinical trial for metastatic melanoma and a Phase II trial for neuroendocrine tumors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,773,107) | $(3,478,020) |
| Operating Loss | $(4,676,102) | $(3,228,584) |
| Derivative Instrument Expense | $(4,466,157) | $(473,401) |
| Research & Development Costs | $3,656,226 | $2,088,444 |
| Cash and Cash Equivalents (End of Period) | $7,435,673 | $14,763,123 |
| Total Current Assets | $9,567,389 | $11,341,193 |
| Total Current Liabilities | $7,449,537 | $1,151,807 |
| Derivative Liability | $7,105,454 | $448,318 |
| Accumulated Deficit | $(56,088,270) | $(47,315,163) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $5.3 million compared to the prior year period. This was driven primarily by a $3.99 million increase in derivative instrument expense and a $1.57 million increase in R&D costs.
- Derivative Liability Surge: The derivative instrument liability increased from $448,318 to $7,105,454. This is due to mark-to-market adjustments on warrants issued in 2007 and 2009, which are classified as liabilities under SFAS 133.
- R&D Acceleration: R&D expenses rose 75.1% year-over-year due to the expansion of the Phase III clinical trial from one center to twelve centers, increasing patient treatment and enrollment costs.
- Liquidity Position: While cash and cash equivalents increased slightly from the beginning of the year ($6.9M to $7.4M), total current assets decreased due to the maturity of short-term investments. The company utilized $4.8 million in cash for operating activities.
Outlook, Management Commentary, and Risks
- Clinical Trial Progress: As of June 30, 2009, 72 patients were enrolled in the Phase III trial (target 92). Between July 1 and July 27, 2009, an additional 7 patients were enrolled, bringing the total to 79. Management expects to complete enrollment in 2009.
- Capital Resources: Management believes current capital is sufficient to fund operations through 2009 and complete the Phase III trial enrollment. However, the company has an accumulated deficit of $56.1 million and expects to continue incurring losses.
- Financing Activities: In June 2009, the company sold 869,565 shares and issued warrants for gross proceeds of $3.0 million. A new Form S-3 registration statement became effective in June 2009, allowing the company to raise up to $60 million in future offerings.
- Executive Change: Effective July 6, 2009, Eamonn Hobbs was appointed President and CEO, replacing Richard Taney.
- Risks: The company faces significant risks regarding the uncertainty of clinical trial results, the timing of FDA approval, and the ability to raise additional capital. There is no assurance the product will ever be approved or generate revenue.
Key Facts for Investor Verification
- Derivative Liability Impact: Verify the valuation assumptions (volatility, interest rates) used for the $7.1 million warrant liability, as fluctuations in stock price significantly impact reported net loss.
- Cash Burn Rate: Confirm the company's ability to fund operations through 2009 given the $4.8 million cash burn in the first six months and the lack of revenue.
- Clinical Trial Milestones: Monitor the completion of the Phase III trial enrollment (target 92 patients) and the subsequent timeline for FDA submission.
- Future Capital Needs: Assess the necessity of future equity dilution or debt financing to fund commercialization efforts post-trial.